ERα在非小细胞肺癌组织中的表达及临床意义

The Expressions of ERα in Non-Small Cell Lung Cancer and Its Clinical Significance

目的探讨ERα受体蛋白在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达及临床意义。方法应用免疫组化S-P法,检测67例非小细胞肺癌、42例正常肺组织(normal lung tissue,NL)中ERα受体蛋白的表达。结果ERα在鳞癌、腺癌、鳞腺癌、大细胞癌阳性率分别为34.21%(13/38)、53.33%(8/15)、66.67%(6/9)、40.00%(2/5),ERα在肺癌组织中总的阳性率为43.28(29/67),ERα在正常肺组织阳性表达率为16.67%(7/42),差异有统计学意义(P<0.05)。在鳞癌组织中ERα主要表达于胞核,在腺癌组织中ERα主要表达于胞浆,ERα的阳性表达与肺癌组织学类型、肿瘤分化程度有关,而与肺癌分期、有无淋巴结转移等无关。ERα蛋白阳性患者预后好于阴性患者。结论ERα受体蛋白的过表达可能参与非小细胞肺癌发生发展,可以作为临床预后的一个参考指标。

Objective To investigate the clinical significance and the expressions of ERα in non-small cell lung cancer（ NSCLC）. Methods Immunohistochemical method was used to examine ERα protein of the sections from 67 cases with NSCLC and 42 normal lung tissues （NL）. Results The positive rates of ERα expressions in squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and large cell carcinoma were 34.21% （ 13/38 ） , 53.33% （ 8/15 ） . 66.67% （ 6/9 ） , 40.00% （2/5） respectively. The positive rates of squamous cell carcinoma and adenocarcinoma were significantly higher than that of normal lung issues （ P 〈 0.05 ）. Besides, the expression area of ERα was often in the nucleus for squamous cell carcinoma and in the cytoplasma for adenocarcinoma. Conclusion The results suggest that overexpressions of ERα involve in genesis and development of non-small cell lung cancer. Detection of ERα could be used as a prognostic factor for the patients.